Cytomedix, Inc. (OTC:CMXI), a Gaithersburg, Md. based biotechnology company, disclosed the compensation of its top executives in a recent regulatory filing.

 

Cytomedix, Inc. develops adult stem cell products that enhance the body's natural  healing processes, particularly for wound and tissue repair.

The company reported net income for 2011 of $0.81 million or $0.02 per basic share compared with a net loss of $2.17 million or $0.05 per share.